Epitope Content Comparison: predicting the immunogenicity of vaccines
Results for "epicc"
Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach
Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach
T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines
2020 Bandrick et al. EpiCC
Predicting Immunogenicity of Vaccines Using EpiCC
SWINE_IAV_IVIS2019_POSTER_v9_final_13Aug
T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin
Modalities
Biologic Therapeutics Our in silico analyses rely on a unique multi-step process that produces a more accurate assessment of immunogenicity, including a T cell epitope characterization process that surpasses conventional epitope mapping by considering regional...
In Silico Immunogenicity Assessment for Vaccines
Over 25 years, vaccinologists, bioinformatics experts, and advanced programmers at EpiVax have developed an integrated, web-based toolkit for computational vaccine design called iVAX™. The toolkit enables the discovery and optimization of the T cell epitope “triggers”...
ISPRI Quantify™
Streamline R&D with actionable immunogenicity data.
Providence-Based Biotech Startup, EpiVax, Celebrates 25th Anniversary
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ -- EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking...
EpiVax: 25 years of Fearless Science
EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998 EpiVax...